Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Radium 223 induces transient functional bone marrow toxicity

ABSTRACT: Radium 223 induces transient functional bone marrow toxicity

PROVIDER: PRJNA735243 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14736832.fastq.gz	Fastqsanger.gz

Items per page:

1 - 1 of 1

Similar Datasets

Radium 223 induces transient functional bone marrow toxicity

Project description:Radium 223 (Rad223) is a bone-seeking, alpha-particle-emitting radionuclide approved for the treatment of patients with metastatic castration resistant prostate cancer and is currently being tested in a variety of clinical trials for primary and metastatic cancers to bone. Clinical evaluation of Rad223 hematologic safety showed a significantly increased rate of neutropenia and thrombocytopenia in patients, hinting at myelosuppression as side effect. In this study we present a preclinical approach to investigate the consequences of Rad223 treatment on bone marrow biology. Rad223 accumulated in bones and induced confined radiation damage, followed by progressive replacement of the impaired areas with adipocyte infiltration, as monitored by three-dimensional multiphoton microscopy, ex vivo. Flow cytometry and single cell transcriptomic analyses on bone marrow hematopoietic populations revealed transient, non-specific Rad223-mediated cytotoxicity on resident populations, including stem, progenitor and mature leukocytes. This was paralleled by a significant decrease of white blood cells and platelets in peripheral blood, which was overcome within 40 days post-treatment. Rad223 exposure did not impair full hematopoietic reconstitution, suggesting that the bone marrow function is not permanently hampered. Our results provide a comprehensive explanation of Rad223 reversible effects on bone marrow cells and exclude long-term myelotoxicity, supporting its safety during treatment of patients at both early and late disease stages.

2023-12-12 | GSE176195 | GEO

miR-223 Bone Marrow Derived Eosinophils

Project description:Gene expression profiling of bone marrow derived eosinophils from miR-223 wildtype or miR-223 deficient mice

2012-08-25 | E-MEXP-3350 | biostudies-arrayexpress

Immature granulocyte in WT and miR-223 KO bone marrow

Project description:To analyze the function of miR-223 in steady-state myelopoiesis.

2022-01-01 | GSE33917 | GEO

GM-CSF cultured WT and miR-223 KO bone marrow

Project description:To analyze the function of miR-223 in ex-vivo cultured bone marrow.

2022-01-01 | GSE33914 | GEO

Blimp1 induces transient metastatic heterogeneity in pancreatic cancer

Project description:Blimp1 induces transient metastatic heterogeneity in pancreatic cancer

| PRJNA356058 | ENA

Obesity promotes Fumonisin B1 toxicity and induces hepatitis

Project description:Obesity promotes Fumonisin B1 toxicity and induces hepatitis

| PRJEB54776 | ENA

Bradyrhizobium sp. USDA 223 isolate:USDA 223

Project description:Bradyrhizobium sp. USDA 223 isolate:USDA 223 Genome sequencing

| PRJNA1115348 | ENA

regulatory changes induced by miR-223 in a monocyte/macrophage cell line.

Project description:We used a multi-omics approach combining transcriptomics, proteomics and metabolomics to study the impact of over-expression and inhibition of the microRNA miR-223, a pleiotropic regulator of metabolic-related disease, in the RAW monocyte-macrophage cell line. We analyzed the levels of proteins, mRNAs, and metabolites in order to identify genes involved in miR-223 regulation, to determine candidate disease biomarkers and potential therapeutic targets. We observed that both up- and down-regulation of miR-223 induced profound changes in the mRNA, protein and metabolite profiles in RAW cells. Microarray-based transcriptomics evidenced a change in 120 genes that were linked predominantly to histone acetylation, bone remodeling and RNA regulation. In addition, 30 out the 120 genes encoded long noncoding RNAs. The nanoLC-MS/MS revealed that 52 proteins were significantly altered when comparing scramble, pre- and anti-miR-223 treatments. Sixteen out of the mRNAs coding these proteins genes are predicted to have binding sites for miR-223. CARM-1, Ube2g2, Cactin and Ndufaf4 were confirmed to be miR-223 targets by western blotting. Analyses using Gene Ontology annotations evidenced association with cell death, splicing and stability of mRNAs, bone remodeling and cell metabolism. miR-223 alteration changed the expression of CARM-1, Ube2g2, Cactin and Ndufaf4 during osteoclastogenesis and macrophage, indicating that these genes are potential biomarkers of these processes. The most important discriminant metabolites found in the metabolomics study were found to be hydrophilic amino acids, carboxylic acids linked to metabolism and pyrimidine nucleotides, indicating that changes in miR-223 expression alter the metabolic profile of cells, and may affect their apoptotic and proliferative state.

2021-03-29 | PXD009844 | Pride

Transient loss of Polycomb components induces an epigenetic cancer fate

Project description:Transient loss of Polycomb components induces an epigenetic cancer fate

| PRJNA918577 | ENA

miR-223 in esophageal adenocarcinoma carcinogenesis

Project description:miR-223 is step-wise increasingly up-regulated in the normal esophagus - Barrett's esophagus -esophageal adenocarcinoma carcinoma sequence. In this study, we aimed to determine the function of miR-223 in esophageal adenocarcinoma carcinogenesis.

2013-02-07 | GSE44120 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data